Send me real-time posts from this site at my email

Watchlist Update: 5-23-2019 - IOVA - Iovance - Analyst Comments

TIGER'S TAKE:  On our trading list, the good news keeps coming in. Exploding higher the last few days.

Iovance Biotherapeutics analyst commentary at Wells Fargo

Iovance Biotherapeutics price target raised to $32 from $23 at Wells Fargo. Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics to $32 from $23 following FDA breakthrough therapy designation for its TIL cell therapy LN-145 in cervical cancer. With ongoing pivotal development in melanoma, the analyst sees a second potential accelerated path to market with breakthrough therapy designation in cervical cancer and sees upside potential to further regulatory update on LN145. Birchenough reiterates an Outperform rating on the shares.

Source: (

$IOVA, Iovance Biotherapeutics, Inc. / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions.

Follow us and check back occasionally for additional articles or comments.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue